Travere Therapeutics Inc (TVTX)

$5.39

-0.06

(-1.1%)▲

Live

Insights on Travere Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 37.09M → 45.05M (in $), with an average increase of 17.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 150.73M → -90.17M (in $), with an average decrease of 159.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 123.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 318.1%

Performance

  • $5.13
    $5.43
    $5.39
    downward going graph

    4.82%

    Downside

    Day's Volatility :5.52%

    Upside

    0.74%

    downward going graph
  • $5.25
    $22.75
    $5.39
    downward going graph

    2.6%

    Downside

    52 Weeks Volatility :76.92%

    Upside

    76.31%

    downward going graph

Returns

PeriodTravere Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-40.44%
1.7%
0.0%
6 Months
-21.81%
11.3%
0.0%
1 Year
-74.04%
5.4%
1.3%
3 Years
-78.03%
13.9%
-22.1%

Highlights

Market Capitalization
436.9M
Book Value
$2.66
Earnings Per Share (EPS)
-5.07
Wall Street Target Price
14.8
Profit Margin
-76.7%
Operating Margin TTM
-183.85%
Return On Assets TTM
-32.22%
Return On Equity TTM
-308.9%
Revenue TTM
145.2M
Revenue Per Share TTM
1.96
Quarterly Revenue Growth YOY
53.6%
Gross Profit TTM
-31.4M
EBITDA
-338.2M
Diluted Eps TTM
-5.07
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.18
EPS Estimate Next Year
-1.75
EPS Estimate Current Quarter
-1.22
EPS Estimate Next Quarter
-0.95

Analyst Recommendation

Buy
    76%Buy
    23%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Travere Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
17
Hold
5
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 174.58%

Current $5.39
Target $14.80

Company Financials

FY18Y/Y Change
Revenue
164.2M
↑ 6.01%
Net Income
-102.7M
↑ 71.9%
Net Profit Margin
-62.51%
↓ 23.96%
FY19Y/Y Change
Revenue
175.3M
↑ 6.75%
Net Income
-146.4M
↑ 42.61%
Net Profit Margin
-83.51%
↓ 21.0%
FY20Y/Y Change
Revenue
198.3M
↑ 13.11%
Net Income
-169.4M
↑ 15.71%
Net Profit Margin
-85.43%
↓ 1.92%
FY21Y/Y Change
Revenue
227.5M
↑ 14.71%
Net Income
-180.1M
↑ 6.29%
Net Profit Margin
-79.16%
↑ 6.27%
FY22Y/Y Change
Revenue
212.0M
↓ 6.8%
Net Income
-278.5M
↑ 54.63%
Net Profit Margin
-131.35%
↓ 52.19%
FY23Y/Y Change
Revenue
145.2M
↓ 31.5%
Net Income
-111.4M
↓ 60.0%
Net Profit Margin
-76.7%
↑ 54.65%
Q3 FY22Q/Q Change
Revenue
53.5M
↓ 1.24%
Net Income
-69.7M
↑ 3.91%
Net Profit Margin
-130.21%
↓ 6.46%
Q4 FY22Q/Q Change
Revenue
55.9M
↑ 4.43%
Net Income
-65.8M
↓ 5.5%
Net Profit Margin
-117.82%
↑ 12.39%
Q1 FY23Q/Q Change
Revenue
57.0M
↑ 2.01%
Net Income
-86.3M
↑ 31.16%
Net Profit Margin
-151.48%
↓ 33.66%
Q2 FY23Q/Q Change
Revenue
59.7M
↑ 4.74%
Net Income
-85.6M
↓ 0.81%
Net Profit Margin
-143.44%
↑ 8.04%
Q3 FY23Q/Q Change
Revenue
37.1M
↓ 37.86%
Net Income
150.7M
↓ 276.03%
Net Profit Margin
406.35%
↑ 549.79%
Q4 FY23Q/Q Change
Revenue
45.1M
↑ 21.47%
Net Income
-90.2M
↓ 159.82%
Net Profit Margin
-200.12%
↓ 606.47%
FY18Y/Y Change
Total Assets
709.2M
↑ 36.29%
Total Liabilities
390.9M
↑ 72.05%
FY19Y/Y Change
Total Assets
604.8M
↓ 14.72%
Total Liabilities
383.6M
↓ 1.87%
FY20Y/Y Change
Total Assets
607.4M
↑ 0.44%
Total Liabilities
396.2M
↑ 3.29%
FY21Y/Y Change
Total Assets
776.6M
↑ 27.85%
Total Liabilities
474.5M
↑ 19.76%
FY22Y/Y Change
Total Assets
672.6M
↓ 13.4%
Total Liabilities
629.7M
↑ 32.71%
FY23Y/Y Change
Total Assets
788.9M
↑ 17.3%
Total Liabilities
588.1M
↓ 6.61%
Q3 FY22Q/Q Change
Total Assets
726.2M
↓ 6.84%
Total Liabilities
625.5M
↑ 0.44%
Q4 FY22Q/Q Change
Total Assets
672.6M
↓ 7.38%
Total Liabilities
629.7M
↑ 0.67%
Q1 FY23Q/Q Change
Total Assets
808.2M
↑ 20.17%
Total Liabilities
619.1M
↓ 1.69%
Q2 FY23Q/Q Change
Total Assets
736.4M
↓ 8.88%
Total Liabilities
619.9M
↑ 0.14%
Q3 FY23Q/Q Change
Total Assets
832.9M
↑ 13.09%
Total Liabilities
553.1M
↓ 10.78%
Q4 FY23Q/Q Change
Total Assets
788.9M
↓ 5.28%
Total Liabilities
588.1M
↑ 6.33%
FY18Y/Y Change
Operating Cash Flow
-25.0M
↓ 437.13%
Investing Cash Flow
-203.3M
↓ 545.79%
Financing Cash Flow
231.9M
↑ 4158.27%
FY19Y/Y Change
Operating Cash Flow
-58.2M
↑ 133.25%
Investing Cash Flow
19.9M
↓ 109.77%
Financing Cash Flow
-2.1M
↓ 100.9%
FY20Y/Y Change
Operating Cash Flow
-42.7M
↓ 26.58%
Investing Cash Flow
-61.3M
↓ 408.75%
Financing Cash Flow
127.7M
↓ 6248.92%
FY21Y/Y Change
Operating Cash Flow
-14.8M
↓ 65.39%
Investing Cash Flow
-137.6M
↑ 124.41%
Financing Cash Flow
231.7M
↑ 81.41%
FY22Y/Y Change
Operating Cash Flow
-186.3M
↑ 1159.4%
Investing Cash Flow
-32.6M
↓ 76.35%
Financing Cash Flow
117.6M
↓ 49.25%
Q3 FY22Q/Q Change
Operating Cash Flow
-39.5M
↑ 7.39%
Investing Cash Flow
10.1M
↓ 125.78%
Financing Cash Flow
2.3M
↑ 174.13%
Q4 FY22Q/Q Change
Operating Cash Flow
-54.6M
↑ 38.24%
Investing Cash Flow
-36.7M
↓ 464.13%
Financing Cash Flow
551.0K
↓ 75.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-81.1M
↑ 48.46%
Investing Cash Flow
-37.0M
↑ 0.92%
Financing Cash Flow
217.0M
↑ 39282.21%
Q2 FY23Q/Q Change
Operating Cash Flow
-69.3M
↓ 14.57%
Investing Cash Flow
-23.6M
↓ 36.41%
Financing Cash Flow
2.3M
↓ 98.96%

Technicals Summary

Sell

Neutral

Buy

Travere Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Travere Therapeutics Inc
Travere Therapeutics Inc
-29.13%
-21.81%
-74.04%
-78.03%
-71.86%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Travere Therapeutics Inc
Travere Therapeutics Inc
NA
NA
NA
-3.18
-3.09
-0.32
NA
2.66
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Travere Therapeutics Inc
Travere Therapeutics Inc
Buy
$436.9M
-71.86%
NA
-76.7%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • BlackRock Inc

    10.40%

  • Armistice Capital, LLC

    9.70%

  • Deep Track Capital, LP

    9.68%

  • Vanguard Group Inc

    7.25%

  • State Street Corporation

    7.03%

  • Macquarie Group Ltd

    6.24%

Corporate Announcements

  • Travere Therapeutics Inc Earnings

    Travere Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Travere Therapeutics Inc
Employees
380
CEO
Dr. Eric M. Dube Ph.D.
Industry
Health Technology

Discover More

FAQs